Irisin Dosage | Protocols, Cycles & Reconstitution

You've done the background reading. You know irisin is the FNDC5-derived myokine that mimics the metabolic benefits of exercise — improving insulin sensitivity, driving fat browning, activating AMPK and PGC-1α signaling in metabolic tissue. What you need now is the practical framework: exactly how much to use, how to mix it, when to inject, how long to run a cycle, and how to stack it intelligently.

This guide skips the origin story and gets to the numbers.

---

Why Dosing Irisin Is Different From Most Peptides

Irisin sits in an unusual position in peptide research. Unlike BPC-157 or Ipamorelin, which have extensive human dosing literature built from clinical trials, most irisin dosing data derives from rodent studies, a handful of ex vivo human tissue experiments, and a growing body of observational data tracking endogenous circulating levels in exercising humans.

That matters because dose translation from rodent to human isn't linear. The standard FDA body surface area (BSA) conversion applies a factor of roughly 12.3 when scaling from mouse to human. A dose of 0.5 mg/kg in a mouse doesn't become 0.5 mg/kg in a human — it becomes approximately 0.04 mg/kg when adjusted for BSA. Miss this conversion and you're either wasting peptide or risking pharmacological effects you didn't intend.

Additionally, endogenous irisin circulates in the 3–10 ng/mL range in sedentary humans and can reach 15–20 ng/mL after acute intense exercise (Boström et al., *Cell*, 2012). Any exogenous protocol should be designed with physiological range in mind — you're trying to replicate or modestly exceed what exercise would produce, not flood receptors at supraphysiological levels without precedent.

With that calibration in place, let's build the protocol.

---

Reconstitution: The Math Before the First Injection

Research-grade irisin is supplied as a lyophilized powder, typically in 1 mg or 2 mg vials. Reconstitution requires bacteriostatic water (BAC water). Do not use sterile water for multi-dose vials — BAC water's 0.9% benzyl alcohol content prevents microbial growth over the 28-day use window.

Standard Reconstitution Protocol

Step 1: Determine your target dose

For a target dose of 100 mcg per injection, with a 1 mg vial:

Step 2: Inject BAC water slowly

Direct the needle toward the glass wall of the vial, not into the powder directly. Let the water run down the side and allow the lyophilized cake to dissolve over 1–2 minutes. Do not shake — gently swirl or roll between your palms.

Step 3: Visual inspection

The reconstituted solution should be clear and colorless. Any cloudiness, particulate matter, or color change indicates degradation or contamination — discard the vial.

Reconstitution Concentration Reference Table

Tip: The 500 mcg/mL concentration is preferred for lower doses because it keeps injection volumes practical on a U100 insulin syringe without requiring volumes under 5 IU, which are difficult to measure accurately.

Storage After Reconstitution

---

Administration Route: Subcutaneous vs. Intravenous

For research purposes, subcutaneous (SubQ) injection is the standard administration route. It provides slower absorption than IV, maintaining more stable plasma levels over a 4–8 hour window rather than the sharp spike-and-crash of intravenous delivery.

IV administration has been used in rodent studies to achieve rapid peak plasma concentrations for mechanistic research, but it offers no practical advantage for metabolic research protocols and carries unnecessary risk.

Preferred injection sites for SubQ delivery:

Rotate sites with each injection to prevent lipodystrophy at a single location. Use a 27–31 gauge, 0.5-inch insulin needle for SubQ delivery. Pinch the skin, insert at 45° (or 90° for individuals with adequate subcutaneous fat), inject slowly over 5–10 seconds, and hold for 5 seconds before withdrawing.

---

Beginner Protocol: Conservative Start for First-Time Researchers

The beginner protocol prioritizes safety and response assessment over maximizing metabolic effect. The goal in weeks 1–2 is to establish that the research subject tolerates exogenous irisin without unexpected immune reactions, injection site responses, or systemic effects.

Beginner Protocol Specifications

Rationale for 50 mcg starting dose: This approximates the lower end of physiologically meaningful concentrations based on BSA-adjusted rodent data. A 2013 study by Zhang et al. in *PLOS ONE* demonstrated measurable improvements in glucose uptake in adipocytes at concentrations equivalent to roughly 40–60 mcg/kg in rodent models, which after BSA correction suggests the 50–75 mcg human range as a meaningful threshold.

Morning timing rationale: Irisin's primary metabolic targets — adipose tissue and skeletal muscle — are most insulin-sensitive in the morning fasted state. Administering irisin before the first meal or before exercise captures the window when AMPK signaling in muscle is most responsive to metabolic input.

What to track during the beginner protocol:

---

Standard Protocol: The Core Research Framework

Once the beginner cycle is complete and tolerance is confirmed, most researchers advance to the standard protocol. This phase is designed for meaningful metabolic research outcomes, including measurable changes in insulin sensitivity, body composition, and energy expenditure markers.

Standard Protocol Specifications

Once Daily vs. Twice Daily Dosing

Irisin's half-life in circulation has not been precisely characterized in humans, but based on its molecular weight (~12 kDa as the circulating fragment) and structural similarity to other fibronectin domain proteins, a half-life of 3–6 hours is a reasonable working estimate for the active circulating form.

This means a single daily injection produces a pulse-like elevation rather than sustained elevation throughout the day. For researchers studying acute metabolic responses — particularly pre-exercise insulin sensitization — once-daily dosing is appropriate and mirrors the natural irisin pulse generated by a single exercise bout.

For researchers focused on chronic remodeling effects — adipose browning, sustained AMPK activation, or bone density markers — twice-daily dosing at 75 mcg per injection (total 150 mcg/day) may provide more sustained receptor engagement without exceeding the daily total.

Twice daily timing:

The 8-Week Standard Protocol in Detail

Weeks 1–2 (Titration phase):

Weeks 3–8 (Full dose phase):

End of cycle assessment:

---

Advanced Protocol: High-Dose and Combination Approaches

The advanced protocol is for experienced researchers who have completed at least one standard cycle and are targeting specific outcomes: maximal adipose browning, synergistic insulin sensitization, or combined body composition and metabolic research.

Advanced Protocol Specifications

Important note on 200–250 mcg dosing: This range is extrapolated from the higher end of rodent efficacy data with BSA correction. There is currently no published human pharmacokinetic study confirming safety or efficacy at this level specifically. The evidence base supporting this dose range is mechanistic and translational, not clinical. Researchers should approach this range with appropriate caution and comprehensive monitoring.

Key finding from Colaianni et al. (2015, *PNAS*): Systemic irisin administration in mice at 7.5 mcg every 3 days (equivalent to approximately 100–150 mcg/day in BSA-adjusted human terms) increased cortical bone mineral density by +3.8% and trabecular bone volume by +9.7% over 8 weeks, with concurrent increases in muscle fiber cross-sectional area. This suggests the 100–200 mcg/day range as potentially relevant for musculoskeletal research applications.

---

Protocol Comparison Table

---

Timing Relative to Exercise: The Critical Variable

Irisin is unique among research peptides because its primary physiological trigger is exercise — specifically, high-intensity resistance and endurance training. This creates a specific timing consideration that doesn't apply to most other peptides.

Pre-Exercise Administration (Recommended)

Administering irisin 30–60 minutes before exercise may amplify the endogenous irisin release triggered by the exercise session itself, creating a combined exogenous + endogenous irisin pulse. The theoretical benefit: higher peak receptor occupancy at the exercise-sensitive timepoint, potentially greater GLUT4 translocation and glucose uptake in contracting muscle.

Boström's original 2012 *Cell* paper demonstrated that exercise-induced FNDC5/irisin was responsible for a significant portion of PGC-1α-mediated UCP1 induction in subcutaneous fat depots. Pre-exercise dosing is designed to front-load this pathway.

Post-Exercise Administration (Alternative)

Some researchers prefer post-exercise dosing on the rationale that endogenous irisin is already elevated from the session, and exogenous irisin administered 15–30 minutes post-exercise prolongs the elevated irisin window rather than stacking with the peak. This may be preferable for researchers targeting sustained adipose browning rather than acute glucose uptake.

Rest Day Dosing

On non-training days, administer in the morning before breakfast. Muscle is still in a recovery and remodeling state for 24–48 hours post-exercise, and morning fasted-state administration maintains irisin exposure during this period.

---

Stacking Strategies

Stack 1: Irisin + MOTS-c for Mitochondrial Metabolic Research

MOTS-c is a mitochondrial-derived peptide that activates AMPK in skeletal muscle and improves glucose uptake through a mechanism that partially overlaps with irisin but also engages distinct pathways — specifically, AMPK activation via folate cycle interference and methionine restriction signaling.

The rationale for combining them: irisin drives FNDC5/PGC-1α → UCP1 induction in adipose, while MOTS-c enhances mitochondrial biogenesis and AMPK in muscle. Together, they target both the fat-burning (adipose browning) and the fuel-utilization (muscle glucose uptake) sides of the metabolic equation simultaneously.

Irisin + MOTS-c Protocol:

Note: MOTS-c and irisin can be injected at the same time from separate syringes into adjacent SubQ sites. Do not combine in the same syringe without confirming compatibility data.

Stack 2: Irisin + 5-Amino-1MQ for Fat Loss Research

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that increases intracellular SAM (S-adenosylmethionine) and drives NAD+ precursor availability, which activates SIRT1 — one of irisin's downstream effectors. The combination creates a dual approach: irisin drives the upstream PGC-1α/FNDC5 axis, while 5-Amino-1MQ enhances the SIRT1-mediated downstream fat oxidation response.

Irisin + 5-Amino-1MQ Protocol:

Stack 3: Irisin + Epithalon for Longevity and Metabolic Aging Research

This stack targets the intersection of metabolic function and biological aging. Epithalon (Epitalon), the tetrapeptide Ala-Glu-Asp-Gly, activates telomerase and has demonstrated antioxidant and neuroendocrine modulating effects in aging models. Metabolic dysfunction and accelerated cellular aging share common upstream drivers — oxidative stress, impaired mitochondrial function, and declining SIRT1 activity.

Irisin's role in this stack is to maintain insulin sensitivity and adipose tissue health (visceral fat accumulation is a key driver of metabolic aging), while Epithalon addresses telomere attrition and oxidative damage at the cellular level.

Irisin + Epithalon Protocol:

Note: Epithalon is typically run in shorter pulse cycles (10 days on, 20 days off) rather than continuous dosing. Irisin runs continuously through the 8-week cycle regardless of Epithalon timing.

---

Titration Strategy: Building to Your Target Dose

Regardless of which protocol you're running, titration is the safest approach to establishing effective dose. Jumping straight to 150–200 mcg on day one provides no baseline response data and makes it harder to attribute any observed effects to irisin specifically.

Recommended Titration Schedule

If at any point during titration you observe unusual local reactions (persistent nodules, significant redness, warmth at injection site lasting >24 hours) or systemic effects (unexpected hypoglycemia, pronounced fatigue, or cardiovascular symptoms), drop back to the previous tolerated dose and hold for one week before re-attempting.

---

Cycle Length and Off-Cycle Planning

Why cycle irisin at all? Unlike small molecules that are cleared rapidly, peptides with receptor-level activity can cause receptor downregulation or desensitization with continuous exposure. While irisin receptor data is still emerging — the integrin αV/β5 complex has been proposed as a primary receptor by Kim et al. (2018) — the precautionary principle supports cycling.

Standard cycle structure:

What to do during the off cycle:

When to Extend a Cycle

If at week 8 you're seeing continued progressive improvement in measured outcomes (declining fasting glucose, improving body composition markers) with no adverse effects, extending to 12 weeks is reasonable. The rodent studies showing bone density and adipose browning effects used treatment durations of 8–16 weeks, suggesting longer cycles may be necessary to capture the full remodeling effects.

---

The Evidence Informing These Doses

Understanding which studies these doses are derived from makes you a better researcher. Here's the critical literature:

Glucose Metabolism and Insulin Sensitivity

Boström et al. (2012, *Cell*) — The landmark paper that characterized irisin as a circulating exercise hormone. Mice given FNDC5 overexpression (effectively chronically elevated irisin) showed +3.6-fold increase in UCP1 expression in subcutaneous fat and improved glucose tolerance on a high-fat diet. The circulating irisin levels achieved were approximately 40–50% above basal, providing the first indication that modest supraphysiological elevation (not extreme) is the target.

Liu et al. (2013, *Metabolism*) — Administered recombinant irisin to diet-induced obese mice at 0.5 mg/kg every other day for 14 days. Fasting glucose dropped by 18%, insulin levels by 22%, and HOMA-IR (insulin resistance index) improved by 31%. After BSA correction, this 0.5 mg/kg mouse dose translates to approximately 40 mcg/kg in humans — for a 75 kg person, roughly 3 mg total, which is in the higher end of the advanced protocol range.

Sanchis-Gomar et al. (2014, *Diabetes*) — Showed that irisin treatment in human adipocytes at physiologically relevant concentrations (5–20 ng/mL, approximating the circulating range after exercise) increased GLUT4 expression by 43% and glucose uptake by 28% ex vivo. This validates the physiological concentration target and supports the idea that doses creating circulating levels in the 5–20 ng/mL range are metabolically meaningful.

Adipose Browning and Energy Expenditure

Zhang et al. (2016, *Endocrinology*) — Recombinant irisin at 1 mcg/mL in cultured human white adipocytes induced UCP1 mRNA expression by 6.4-fold and increased mitochondrial content. This was a cell culture model, so direct dose translation doesn't apply, but it confirms that irisin is directly active on human adipocytes at concentrations achievable with the standard protocol.

Lee et al. (2014, *American Journal of Physiology*) — In a 10-week mouse study, irisin-treated animals on a high-fat diet showed 8% less total body fat compared to controls, with preferential reduction in visceral adipose tissue. The dose used (0.5 mcg/g every other day) again supports the 100–150 mcg/day range for human research when BSA-adjusted.

Bone and Muscle Effects

Colaianni et al. (2015, *PNAS*) — One of the most compelling mechanistic studies. Irisin at 7.5 mcg every 3 days in mice (approximately 100–150 mcg/day BSA-adjusted human equivalent) produced measurable cortical bone density gains (+3.8%) and muscle fiber hypertrophy at 8 weeks. This is the study most commonly cited to support irisin's role beyond metabolic research.

Huh et al. (2014, *Journal of Bone and Mineral Research*) — Demonstrated irisin receptors on osteoblasts and osteoclasts, with irisin treatment increasing osteocalcin production by 40% and reducing osteoclast activity. Provides the mechanistic basis for the bone density findings in Colaianni et al.

Comparison Table: Key Irisin Studies

---

Safety Profile and Side Effect Management

Common and Expected Effects

Injection site reactions are the most commonly reported effect with any SubQ peptide. For irisin specifically, mild redness or a small raised area at the injection site is normal for the first 1–2 hours. Persistent nodules (lasting >24 hours) suggest either poor technique (not enough SubQ fat, intramuscular injection) or local immune reaction to the peptide. Rotating injection sites consistently prevents buildup.

Transient fatigue in the first 1–2 weeks of a new cycle has been anecdotally reported. This may reflect metabolic adaptation as the peptide begins shifting fuel utilization patterns — similar to the transient fatigue some report when beginning a ketogenic diet or significantly increasing exercise volume. It typically resolves by week 2–3.

Appetite changes — both increased and decreased appetite have been reported. Irisin's interaction with hypothalamic circuits (Piya et al., 2014 demonstrated irisin expression in the hypothalamus) may account for appetite modulation. If pronounced appetite suppression interferes with adequate caloric intake during a training protocol, consider timing the injection further from meal times.

Monitoring Parameters

Theoretical Risks

Immune response to recombinant protein: Irisin is a protein, and all exogenous proteins carry some risk of triggering an immune response, from mild (local reaction) to rare (systemic allergic response). Using high-purity, verified research-grade irisin from a vendor providing third-party HPLC and mass spectrometry data significantly reduces this risk by ensuring you're injecting what you think you're injecting.

Hypoglycemia risk: Given irisin's demonstrated ability to increase GLUT4 expression and glucose uptake in muscle and fat, combining exogenous irisin with insulin, GLP-1 agonists, or other glucose-lowering agents carries theoretical additive hypoglycemia risk. Researchers using irisin alongside Semaglutide or Liraglutide should monitor glucose closely and consider reducing the GLP-1 dose during the irisin cycle.

Bone turnover acceleration: In models showing irisin's bone anabolic effects, there was also evidence of increased bone remodeling activity. For researchers with pre-existing bone conditions, the implications are uncertain without more human data.

Contraindications

---

How Irisin Compares to Related Metabolic Peptides

The table illustrates that irisin occupies a unique position: it's the only peptide in this category with documented effects across adipose, muscle, AND bone simultaneously, and it has the strongest mechanistic connection to exercise physiology. AOD-9604 is more narrowly focused on lipolysis, while MOTS-c is primarily a mitochondrial/AMPK activator. Irisin's multi-tissue reach makes it the broadest metabolic research tool in this class.

---

Practical Injection Protocol: Step-by-Step

For researchers who want a complete reference for each injection:

Equipment needed:

Procedure:

1. Remove vial from refrigerator 10–15 minutes before injection

2. Wash hands thoroughly

3. Wipe vial septum with alcohol swab; allow to dry 30 seconds

4. Draw back syringe plunger to your target volume (e.g., 20 IU for 100 mcg at 500 mcg/mL concentration)

5. Insert needle into vial, inject the air, then invert vial and draw the solution

6. Check for air bubbles — tap syringe and expel small bubbles

7. Choose injection site and clean with alcohol swab; allow to dry

8. Pinch skin between thumb and forefinger

9. Insert needle at 45° (or 90° with adequate SubQ fat)

10. Inject slowly over 5–10 seconds

11. Hold needle in place for 5 seconds after injection

12. Withdraw needle; apply gentle pressure with swab (do not rub)

13. Dispose of needle immediately in sharps container

14. Record: date, time, dose, injection site, any observations

Keeping a simple injection log (even a notes app on your phone) makes pattern recognition possible. If a side effect emerges, you want to know whether it correlates with a specific injection site, a dose increase, or a timing change.

---

What the Research Doesn't Yet Tell Us

Honest protocol design requires acknowledging the gaps. Several questions remain unanswered in the irisin literature:

Receptor identity in humans: The integrin αV/β5 receptor identified by Kim et al. (2018) in mice has not been fully validated in human metabolic tissue. If the receptor pharmacology differs between species, dose translation becomes more uncertain.

Oral bioavailability: Irisin is a protein and is expected to be degraded by gut proteases. There is no validated oral form currently. Some researchers have explored intranasal delivery based on irisin's documented effects on the hypothalamus and hippocampus, but bioavailability data for intranasal irisin doesn't yet exist in published form.

Long-term safety in humans: The longest human observational studies track endogenous irisin, not exogenously administered irisin. The safety profile of exogenous irisin over 12+ months is unknown.

Optimal dosing interval: Whether once-daily or twice-daily dosing produces superior outcomes for specific endpoints (fat browning vs. glucose control vs. bone density) hasn't been tested in a controlled comparative study.

Sex differences: Most rodent studies have used male animals. Given that estrogen modulates FNDC5 expression and irisin secretion in females, female researchers may need different dosing considerations — this remains an open question.

These aren't reasons to avoid irisin research. They're the specific questions that make rigorous, well-documented research protocols valuable.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions about irisin dosing? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com